Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2)
Trumper, L. Pro, B. Horwitz, S. O'Connor, O. Tilly, H. Choi, I. Gritti, G. Fox, C. Alpdogan, O. Mayer, J.
Trumper, L.
Pro, B.
Horwitz, S.
O'Connor, O.
Tilly, H.
Choi, I.
Gritti, G.
Fox, C.
Alpdogan, O.
Mayer, J.
Citations
Altmetric:
Abstract
Introduction: Retreatment of pts with relapsed CD30+ Hodgkin lymphoma
or systemic anaplastic large cell lymphoma (sALCL) with BV
monotherapy showed encouraging antitumor activity (Bartlett 2014).
We report exploratory analyses of pts in the phase 3 ECHELON-2 study
(NCT01777152) retreated with BV after frontline BV + cyclophosphamide,
doxorubicin, and prednisone (A+CHP).
Methods: In ECHELON-2, data on subsequent anticancer therapies
were collected, including BV-based regimens, after frontline A+CHP or
CHP+vincristine. Investigator response assessments used the Revised Response
Criteria for Malignant Lymphoma (Cheson 2007). Safety data were
not collected for subsequent anticancer therapy.
Results: In total, 10% of A+CHP pts (23/226) were retreated with BV after
PD (median age 62 yrs [range 26-77]). Most had ALK- sALCL (16/23
[70%]). Objective response rate (best response) per investigator (INV) after
frontline A+CHP was 91% (21/23 [15 CR, 6 PR]); 2 pts (9%) had a best
response of SD. Thirteen pts (57%) received consolidative stem cell transplant
(SCT) after frontline therapy, 6 pts (26%) received intervening therapy
before BV retreatment. In most pts (19/23 [83%]), first retreatment
was BV monotherapy. Median time from frontline therapy to retreatment
was 12.3 mos (range 3-50).
ORR per INV after initial BV retreatment was 57% (13/23 [10 CR, 3 PR])
(Table). Median duration of initial BV retreatment was 2.1 mos (range
0-18). Four pts who had a CR with frontline A+CHP received >1 subsequent
retreatment with BV. Of these, 2 pts had a CR after initial BV
retreatment, 1 pt had PD after initial BV retreatment and a CR after allo-
SCT and subsequent BV retreatment, and 1 pt had a CR after 3 subsequent
BV retreatments.
Conclusions: In this post-hoc analysis of ECHELON-2 pts who were retreated
with BV after frontline A+CHP, 57% had an objective response to BV retreatment in first relapse. Therefore BV retreatment is active in relapsed treatment even after relapsed treatment.
Affiliation
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Trumper L, Pro B, Horwitz S, O'Connor O, Tilly H, Choi I, et al. Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2). Oncology Research and Treatment. 2020;43(SUPPL 4):119-